Okomera

Executive Summary

Okomera is a French pre-clinical stage company developing a microfluidic chip platform for personalized cancer therapy selection. By culturing patient-derived tumor cells as 3D spheroids on chips, the platform enables simultaneous testing of multiple therapies including chemotherapy, immunotherapy, and cell therapy. This approach aims to accelerate treatment decisions and improve outcomes by tailoring therapy to individual tumor biology. Founded in 2020 and based in Paris, Okomera operates in the diagnostics space with a focus on oncology. While no funding rounds or partnerships have been disclosed, the technology addresses a critical need in precision oncology. The company is currently advancing its platform toward clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Initial Preclinical Data Publication50% success
• Q1 2027Pharma Partnership for Co-Development30% success